{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:01:36Z","timestamp":1789740096223,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100020595","name":"Damascus University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020595","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ViennaLab Diagnostics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16440-1","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:11:21Z","timestamp":1782871881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive CYP2D6 genotyping improves phenotype classification and highlights methodological pitfalls in tamoxifen-treated breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Linda","family":"Alkebbeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Berndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Oberkanins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Kenj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Kriegsh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama A.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"9793","key":"16440_CR1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"EBCTC Group","year":"2011","unstructured":"Group EBCTC. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. lancet. 2011;378(9793):771\u201384.","journal-title":"lancet"},{"issue":"5","key":"16440_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423\u201338.","journal-title":"J Clin Oncol"},{"issue":"3","key":"16440_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrd1031","volume":"2","author":"VC Jordan","year":"2003","unstructured":"Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205\u201313.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"16440_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","volume":"80","author":"S Borges","year":"2006","unstructured":"Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80(1):61\u201374.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"16440_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"16440_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cpt.910","volume":"103","author":"A Gaedigk","year":"2018","unstructured":"Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl\u2010Carrillo M, Klein TE, et al. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2018;103(3):399\u2013401.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"16440_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cpt.1007","volume":"103","author":"MP Goetz","year":"2018","unstructured":"Goetz MP, Sangkuhl K, Guchelaar H, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018;103(5):770\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"16440_CR8","doi-asserted-by":"crossref","unstructured":"Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009 [cited 2026 Jan 7];302(13):1429\u201336. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19809024\/","DOI":"10.1001\/jama.2009.1420"},{"issue":"1","key":"16440_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1186\/s12885-022-10148-8","volume":"22","author":"Al-khalilW Ismail","year":"2022","unstructured":"Ismail Al-khalilW, Al-Salhi L, Rijjal S, Aljamali M, Youssef LA. The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. BMC Cancer. 2022;22(1):1067.","journal-title":"BMC Cancer"},{"issue":"2","key":"16440_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10549-012-2074-9","volume":"134","author":"J Gjerde","year":"2012","unstructured":"Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, et al. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat. 2012;134(2):693\u2013700.","journal-title":"Breast Cancer Res Treat"},{"key":"16440_CR11","unstructured":"Assay for the molecular analysis of cytochrome P450. isozyme CYP2D6 genotypes. [cited 2026 Apr 24]. Available from: https:\/\/www.viennalab.com\/products\/pharmacogenetics\/pgx-cyp2d6?cookie=yes"},{"issue":"3","key":"16440_CR12","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"16440_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40246-022-00378-z","volume":"16","author":"M Alali","year":"2022","unstructured":"Alali M, Ismail Al-khalil W, Rijjal S, Al-Salhi L, Saifo M, Youssef LA. Frequencies of CYP2D6 genetic polymorphisms in Arab populations. Hum Genomics. 2022;16(1):6.","journal-title":"Hum Genomics"},{"issue":"11","key":"16440_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/sj.ejhg.5201243","volume":"12","author":"S Fuselli","year":"2004","unstructured":"Fuselli S, Dupanloup I, Frigato E, Cruciani F, Scozzari R, Moral P, et al. Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet. 2004;12(11):916\u201324.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"16440_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1179\/102453310X12583347010214","volume":"15","author":"OE Soliman","year":"2010","unstructured":"Soliman OE, Yahia S, Shouma A, Shafiek HK, Fouda AE, Azzam H, et al. Reverse hybridization StripAssay detection of \u03b2-thalassemia mutations in northeast Egypt. Hematology. 2010;15(3):182\u20136.","journal-title":"Hematology"},{"issue":"1","key":"16440_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/109065704323016049","volume":"8","author":"V Delague","year":"2004","unstructured":"Delague V, Kriegsh\u00e4user G, Oberkanins C, M\u00e9garban\u00e9 A. Reverse-hybridization vs. DNA sequencing in the molecular diagnosis of familial Mediterranean fever. Genet Test. 2004;8(1):65\u20138.","journal-title":"Genet Test"},{"issue":"3","key":"16440_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1155\/JBB.2005.248","volume":"2005","author":"L Bodin","year":"2005","unstructured":"Bodin L, Beaune PH, Loriot MA. Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. Biomed Res Int. 2005;2005(3):248\u201353.","journal-title":"Biomed Res Int"},{"issue":"12","key":"16440_CR18","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.7314\/APJCP.2012.13.12.6101","volume":"13","author":"S Motamedi","year":"2012","unstructured":"Motamedi S, Majidzadeh K, Mazaheri M, Anbiaie R, Mortazavizadeh SMR, Esmaeili R. Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients. Asian Pac J Cancer Prev. 2012;13(12):6101\u20134.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"16440_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00280-012-1891-1","volume":"70","author":"SE Damodaran","year":"2012","unstructured":"Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol. 2012;70(1):75\u201381.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"36","key":"16440_CR20","doi-asserted-by":"publisher","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","volume":"23","author":"MP Goetz","year":"2005","unstructured":"Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"16440_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1200\/JCO.2009.25.7246","volume":"28","author":"K Kiyotani","year":"2010","unstructured":"Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28(8):1287\u201393.","journal-title":"J Clin Oncol"},{"key":"16440_CR22","doi-asserted-by":"crossref","unstructured":"Ram\u00f3n T, Altes A, Pare L, Del Rio E, Alonso C, Barnadas A et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 2010;119(1):33\u20138.","DOI":"10.1007\/s10549-009-0328-y"},{"issue":"6","key":"16440_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1\u201398 trial. J Natl Cancer Inst. 2012;104(6):441\u201351.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"16440_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/cts.12707","volume":"13","author":"JM Nardin","year":"2020","unstructured":"Nardin JM, Schroth W, Almeida TA, M\u00fcrdter T, Picolotto S, Vendramini ECL, et al. The influences of adherence to tamoxifen and CYP2D6 pharmacogenetics on plasma concentrations of the active metabolite (Z)-endoxifen in breast cancer. Clin Transl Sci. 2020;13(2):284\u201392.","journal-title":"Clin Transl Sci"},{"issue":"59","key":"16440_CR25","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.18632\/oncotarget.22220","volume":"8","author":"HI Woo","year":"2017","unstructured":"Woo HI, Lee SK, Kim J, Kim SW, Yu J, Bae SY, et al. Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget. 2017;8(59):100296.","journal-title":"Oncotarget"},{"issue":"2","key":"16440_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1200\/JCO.2012.44.6625","volume":"31","author":"H Brauch","year":"2012","unstructured":"Brauch H, Schroth W, Goetz MP, M\u00fcrdter TE, Winter S, Ingle JN, et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2012;31(2):176.","journal-title":"J Clin Oncol"},{"issue":"3","key":"16440_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/jpm11030201","volume":"11","author":"T Helland","year":"2021","unstructured":"Helland T, Alsomairy S, Lin C, S\u00f8iland H, Mellgren G, Hertz DL. Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer. J Pers Med. 2021;11(3):201.","journal-title":"J Pers Med"},{"issue":"3","key":"16440_CR28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/cpt.3238","volume":"116","author":"AM Mc Laughlin","year":"2024","unstructured":"Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, et al. Nonlinear Mixed-Effects Model of Z\u2010Endoxifen Concentrations in Tamoxifen\u2010Treated Patients from the CEPAM Cohort. Clin Pharmacol Ther. 2024;116(3):690\u2013702.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16440-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16440-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16440-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:02:17Z","timestamp":1789736537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16440-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16440"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16440-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and was approved by the Scientific Research Bioethics Committee at the Faculty of Pharmacy, Damascus University.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anne Berndt and Christian Oberkanins are affiliated with ViennaLab Diagnostics GmbH, Vienna, Austria, a company involved in the development of molecular diagnostic assays, including assays used in this study. These authors contributed scientific and technical expertise related to CYP2D6 genotyping and molecular interpretation. All clinical and statistical analyses were independently performed by the academic investigators. The remaining authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1112"}}